EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
Want to see EYPT full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.93Last Year’s EPS
-0.85Same Quarter Last Year
Strong Buy
Based on 10 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed robust clinical and operational momentum: imminent Phase III wet AMD readouts, strong DME enrollment, favorable Phase II data and a differentiated MOA, supported by manufacturing and commercial preparations. Offsetting this are steep year-over-year revenue decline (driven by prior deferred revenue recognition), rising operating expenses, a larger quarterly net loss and a notable quarter-over-quarter cash reduction. Management projects cash runway into Q4 2027, and masked safety data and DSMC recommendations to date are favorable. Overall, the clinical and strategic positives tied to near-term pivotal catalysts moderately outweigh the financial headwinds.Company Guidance
Imminent Phase III Wet AMD Readouts
Top-line data for pivotal Phase III LUGANO expected mid-year 2026 with LUCIA to follow shortly thereafter; company positions DURAVYU to potentially be first-to-market among sustained-release programs.
Strong DME Phase III Enrollment Momentum
Phase III DME trials (COMO and CAPRI) initiated end of February 2026 with over one-third (>33%) of patients enrolled across both trials and an ambitious goal of full enrollment in Q3 2026; top-line DME data expected H2 2027.
Robust Phase II Clinical Evidence and Durable Efficacy
Across >190 patients in 4 completed trials, DURAVYU showed durable efficacy and a favorable safety profile; VERONA Phase II demonstrated ~4–5 letters vision improvement and ~50-micron anatomic improvement versus aflibercept at week 4.
Favorable Safety/Low Discontinuation Rate
Low discontinuation rate of about 5% in LUGANO/LUCIA (well below the ~10% yearly average in wet AMD trials); masked safety reviews to date show no new safety signals and two consecutive positive DSMC recommendations with a third review scheduled.
Differentiated Multi-Mechanism of Action (MOA)
Preclinical and ARVO-presented data indicate vorolanib (DURAVYU active) inhibits VEGF, PDGF and demonstrates JAK1-mediated IL-6 signaling inhibition, supporting potential anti-inflammatory synergy and clinical differentiation versus current anti-VEGF biologics.
Commercial and Manufacturing Readiness
cGMP Northbridge manufacturing facility online for >1 year supporting anticipated CMC/NDA submission and potential commercial supply; added Chief Commercial Officer and expanded commercial/regulatory teams; product can be shipped/stored at ambient temperature and administered via standard in-office intravitreal injection.
Adequate Near-Term Liquidity to Reach Major Milestones
Cash, cash equivalents and marketable securities totaled $223.0 million as of March 31, 2026; company expects current cash to fund operations into Q4 2027 and through key Phase III wet AMD milestones.
EYPT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
EYPT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 06, 2026 | $13.75 | $13.35 | -2.91% |
Mar 04, 2026 | $18.32 | $18.00 | -1.75% |
Nov 05, 2025 | $12.39 | $11.02 | -11.10% |
Aug 06, 2025 | $10.89 | $10.58 | -2.85% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does EyePoint Pharmaceuticals Inc (EYPT) report earnings?
EyePoint Pharmaceuticals Inc (EYPT) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).
What is EyePoint Pharmaceuticals Inc (EYPT) earnings time?
EyePoint Pharmaceuticals Inc (EYPT) earnings time is at Aug 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EYPT EPS forecast?
EYPT EPS forecast for the fiscal quarter 2026 (Q2) is -0.93.